Principal Investigator: Jenny Workman
Keywords: Clinical Trial , Pediatrics Department: Pediatric Administration
IRB Number: 00130346
Specialty: Pediatrics, General
Sub Specialties:
Recruitment Status: Recruiting

Contact Information

Evan Heller

Brief Summary

The long-term goal of this research is to improve outcomes of children with septic shock. The overall objective is to conduct a multi-center, international trial examining adjunctive hydrocortisone treatment of children with refractory septic shock. The investigators hypothesize that hydrocortisone, compared to placebo, will decrease the proportion of subjects with poor outcomes, defined as death or severe, residual HRQL decrement, 28 days following study enrollment. The investigators further hypothesize that this beneficial effect will be realized in the absence of significant adverse events potentially attributable to hydrocortisone. We will test the hypothesis that biomarker-based prognostic and predictive enrichment strategies can improve our ability to identify which children with septic shock are more likely to benefit from adjunctive hydrocortisone.

Inclusion Criteria


Exclusion Criteria